Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Does HER2 status or response to neoadjuvant therapy influence your decision to use ovarian function suppression in premenopausal patients with ER+ HER2+ tumors?
Related Questions
How do you approach a breast cancer patient with outside pathology returning as HER2 positive on FISH but internal pathology review showing conflicting results and HER2 negative on FISH on same sample?
What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?
Is it okay to send an Oncotype solely for prognostic purposes to a patient who doesn't want chemotherapy or an elderly patient with poor PS?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
Would you give AC followed by Taxol or TC for luminal type B, clinical high risk, breast cancer?
Would you offer adjuvant abemaciclib to young, premenopausal women desiring more children who meet criteria for the same based on monarchE trial?
As a clinician, what are the management differences between lobular and ductal carcinoma of the breast?
In a patient with early stage HER2+ breast cancer s/p surgery, would you consider a noncytotoxic chemotherapy approach with anti-Her2 therapy alone if the PS is borderline and/or patient declines chemotherapy?
